Summary
Fourteen normotensive patients with liver disease (6 with cirrhosis and 8 with chronic hepatitis) and 7 healthy volunteers were given a single oral dose of nilvadipine 2 mg. In addition, nilvadipine 4 mg was administered orally twice daily for several months to 6 hypertensive patients with mild liver dysfunction and 18 hypertensives with normal liver function.
A significant increase in plasma nilvadipine was found in the patients with cirrhosis as compared both to the normal and chronic hepatitis subjects; the time to peak concentration was similar among the three groups.
The peak plasma nilvadipine concentration was closely correlated both with the serum albumin level and the retention of indocyanine green. Changes in blood pressure, pulse rate and various vasoactive hormones following a single oral dose of nilvadipine did not differ between the groups.
Thus, an increase in plasma nilvadipine relative to the level in normal subjects was demonstrated in patients with cirrhosis following a single oral dose, as well as in patients with slight liver dysfunction following long-term oral administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mizuno K, Hashimoto S, Yabe R, Kunii N, Niimura S, Tani M, Watari H, Fukuchi S (1986) Antihypertensive effect of a new calcium blocker, FK 235, in essential hypertension. Res Commun Chem Pathol Pharmacol 52: 3–14
Terakawa M, Tokuma Y, Shishido A, Noguchi H (1986) Pharmacokinetics of nilvadipine in healthy volunteers. J Clin Pharmacol 27: 111–117
Takabatake T, Yamamoto Y, Nakamura S, Hashimoto N, Satoh S, Yamada Y, Ohta H, Hattori N (1987) Effect of the calcium antagonist nilvadipine on hemodynamics at rest and during cold stimulation in essential hypertension. Eur J Clin Pharmacol 33: 215–219
Terakawa M, Tokuma Y, Kuwahara N, Shishido A, Noguchi H (1988) Multiple-dose pharmacokinetics of nilvadipine in healthy volunteers. J Clin Pharmacol 28: 350–355
Niwa T, Tokuma Y, Nakagawa K, Noguchi H (1989) Stereoselective oxidation of nilvadipine, a new dihydropyridine calcium antagonist, in rat and dog liver. Drug Metab Disposit 17: 64–68
Kleinbloesem CH, van Harten J, Wilson JPH, Danhof M, van Brummelen P (1986) Nifedipine: Kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther 40: 21–28
Ene MD, Roberts CJC (1987) Pharmacokinetics of nifedipine after oral administration in chronic hepatic disease. J Clin Pharmacol 27: 1001–1004
Lejeune P, Desager JP, Meunier H, Harvengt C (1988) Kinetics of a single dose combination of nifedipine/acebutolol in patients with chronic liver disease. Int J Clin Pharmacol Ther Toxicol 26: 513–516
Lasseter LC, Shamblen EC, Murdoch AA, et al. (1984) Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. J Cardiovasc Pharmacol 6: s977-s981
Dylewicz P, Kirch W, Santos SR, Hutt HJ, Mönig H, Ohnhuans EE (1987) Bioavailability and elimination of nitrendipine in liver disease. Eur J Clin Pharmacol 32: 563–568
Eichelbaum M, Mikus G, Mast V, Fischer C, Kuhlmann U, Machleidt C (1988) Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. J Cardiovasc Pharmacol 12 [Suppl 4]: s6-s10
Zilly W, Rämsch KD, Gothe M (1988) Disposition of nitrendipine in patients with chronic liver disease. J Cardiovasc Pharmacol 12 [Suppl 4]: s175-s177
Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ (1990) The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. Clin Pharmacol Ther 47: 463–469
van Harten J, van Brummelen P, Wilson JHP, Lodewijks MThM, Breimer DD (1988) Nisoldipine kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. Eur J Clin Pharmacol 34: 387–394
Gengo FM, Fagan SC, Krol G, Bernhard H (1987) Nimodipine disposition and hemodynamic effects in patients with cirrhosis and age-matched controls. Br J Clin Pharmacol 23: 47–53
Caesar J, Shaldon S, Chiandussi L et al. (1961) The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 21: 43
Niwa T, Tokuma Y, Noguchi H (1987) Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog. Res Commun Chem Pathol Pharmacol 55: 75–88
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takata, Y., Yoshizumi, T., Ito, Y. et al. Elevated plasma nilvadipine concentration after single and chronic oral administration to patients with chronic liver disease. Eur J Clin Pharmacol 42, 475–479 (1992). https://doi.org/10.1007/BF00314853
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314853